Synthekine has 6 close competitors: Alloy Therapeutics, MOMA Therapeutics, Encoded Therapeutics.
Sector, valuation and status for each competitor.
A private valuation and a public market cap share one column; each row names its basis and date.
InsitroBiotech developing engineered cytokine therapies for cancer and autoimmune disease
Synthekine competes with 6 companies here: Alloy Therapeutics, MOMA Therapeutics, Encoded Therapeutics, Kriya Therapeutics, Halda Therapeutics, Insitro.
Synthekine is a biotechnology company that applies protein engineering platforms to develop cytokine therapeutics for cancer and autoimmune disease, aiming to unlock the efficacy of cytokines while avoiding the toxicity that comes from their pleiotropic effects on the immune system.
Synthekine's total funding stands at $289.5M over 3 rounds.
Synthekine's most recent round was Series B, raising $107.5M in June 2021.
Synthekine's lead investors include Deerfield Management and Janus Henderson Investors.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
